Treatment of chronic lymphocytic leukemia and related disorders
Neoplastic Diseases of the Blood, Page: 103-119
2013
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Book Chapter Description
According to SEER data, between 2003 and 2007, the median age at diagnosis for chronic lymphocytic leukemia was 72 years and age-adjusted incidence rate was 4.2 per 100,000 men and women per year. A European study estimated the 1- and 5-year prevalence rate of CLL in European Union countries to be 0.2/10,000 and 0.9/10,000, respectively [1].
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84929552397&origin=inward; http://dx.doi.org/10.1007/978-1-4614-3764-2_9; https://link.springer.com/10.1007/978-1-4614-3764-2_9; http://www.springerlink.com/index/10.1007/978-1-4614-3764-2_9; http://www.springerlink.com/index/pdf/10.1007/978-1-4614-3764-2_9; https://dx.doi.org/10.1007/978-1-4614-3764-2_9; https://link.springer.com/chapter/10.1007/978-1-4614-3764-2_9
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know